Interventional cardiology

Malaysia's Fight Against Cardiovascular Disease

Retrieved on: 
Friday, October 6, 2023
Cardiovascular disease, Health, Bukit Tinggi Medical Centre, Hospital, CHIP, Silver, Risk, Tourism, Bandar Sunway, Operation, Interventional cardiology, CVD, World Health Organization, CT, Growth, Consultant, World Heart Federation, Infection, Complex, City, PCSK9, Patient, Fatality, Medical device, Medical imaging

KUALA LUMPUR, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cardiovascular diseases (CVDs) present a substantial global health concern, and Malaysia, is not immune to this health issue. As reported by the World Health Organization, CVDs contribute to nearly 25% of all fatalities in the country. However, the silver lining lies in early detection, which can potentially prevent fatal outcomes. To aid in the early identification of potential CVDs, five hospitals in Malaysia, namely, Bukit Tinggi Medical Centre (BTMC) in Klang, Selangor; Cardio Vascular Sentral Kuala Lumpur (CVSKL) in Kuala Lumpur; Mahkota Heart Centre in Melaka; and Sunway Medical Centre in Selangor, have adopted innovative screening procedures as part of their commitment to advancing cardiovascular health in the country.

Key Points: 
  • Dr. Yew Kuan Leong, Consultant Cardiologist at BTMC, stresses the importance of early cardiac screening and appropriate prevention in the fight against heart disease.
  • "Elevated LDL-Cholesterol levels is a major risk factor for heart disease and can remain high despite adequate oral cholesterol-lowering drugs.
  • “We believe actively involving patients in their own well-being plays an important role in ensuring good long-term cardiovascular health.
  • This fusion of healthcare and tourism makes Malaysia the ultimate destination for cardiovascular treatment and memorable travel experiences.

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

Retrieved on: 
Monday, October 16, 2023
Health, FDA, Medical Devices, Other Science, Science, Cardiology, Biotechnology, Diagnosis, Cardiovascular disease, BMI, Multimedia, US, Prevalence, AI, IGS, Motion, Stent, Interventional cardiology, Canton, CVD, Workflow, PLUS, Intervention, GE HealthCare, GE, Pulse, Noise, TCT, Patient, US FDA, Medical imaging, Medical device, Allia

Today, GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings.

Key Points: 
  • Today, GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company’s image guided system (IGS) offerings.
  • Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size.
  • View the full release here: https://www.businesswire.com/news/home/20231016347394/en/
    Building on the award-winning Allia platform for image guided therapies, GE HealthCare's new Allia IGS Pulse was designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology.
  • Since January 2023, Allia IGS Pulse has been in pilot operations at Clinique Pasteur - Toulouse in Toulouse, France.

Results from Magenta Medical's US Early Feasibility Study of the World's Smallest and Most Powerful Heart Pump to be Highlighted at TCT 2023

Retrieved on: 
Tuesday, October 10, 2023
Coronary artery disease, Mount Sinai Hospital (Manhattan), Percutaneous coronary intervention, Safety, Hospital, Teaching hospital, Diagnosis, Cardiology, Mount Sinai Hospital, Magenta, Ventricular assist device, Interventional cardiology, Philippine Heart Center, North Shore University Hospital, St. Francis Hospital, TCT, Patient, Pharmaceutical industry, Medical device

KADIMA, Israel , Oct. 10, 2023 /PRNewswire/ --Results from Magenta Medical's Early Feasibility Study of the Elevate™ System, for the high-risk percutaneous coronary intervention (HR-PCI) indication, will be announced in an oral presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation in San Francisco. Elevate™ is the world's smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD).

Key Points: 
  • Elevate™ is the world's smallest and most powerful percutaneous Left Ventricular Assist Device (pLVAD).
  • Presentation title: Magenta Elevate™: First US Experience with High-Output, Low-French Size Percutaneous Mechanical Circulatory Support
    Session: TCT Innovation V: Innovation in Coronary Disease Diagnosis and Therapies/Featured Technological Trends: Percutaneous Mechanical Circulatory Support.
  • Magenta's US Early Feasibility Study was initiated to evaluate the safety and feasibility of the Elevate™ System in providing temporary mechanical circulatory support during HR-PCI procedures.
  • Fifteen patients were treated in the study at the Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital.

Malaysia's Fight Against Cardiovascular Disease

Retrieved on: 
Wednesday, October 4, 2023
Infection, World Heart Federation, CVD, CT, Tourism, Consultant, Silver, Fatality, Bukit Tinggi Medical Centre, Interventional cardiology, CHIP, Hospital, Operation, Patient, Bandar Sunway, Risk, PCSK9, Growth, City, Health, Cardiovascular disease, World Health Organization, Complex, Medical device, Medical imaging

Dr. Yew Kuan Leong, Consultant Cardiologist at BTMC, stresses the importance of early cardiac screening and appropriate prevention in the fight against heart disease.

Key Points: 
  • Dr. Yew Kuan Leong, Consultant Cardiologist at BTMC, stresses the importance of early cardiac screening and appropriate prevention in the fight against heart disease.
  • “Elevated LDL-Cholesterol levels is a major risk factor for heart disease and can remain high despite adequate oral cholesterol-lowering drugs.
  • “We believe actively involving patients in their own well-being plays an important role in ensuring good long-term cardiovascular health.
  • This fusion of healthcare and tourism makes Malaysia the ultimate destination for cardiovascular treatment and memorable travel experiences.

St. Joseph's Children's Hospital Implants 250th Pulmonary Valve Without Open-Heart Surgery

Retrieved on: 
Tuesday, October 3, 2023
Heart, Partnership, Ventricular septal defect, Stenosis, 250th Tunnelling Company, Cardiac catheterization, Leg, UPMC Children's Hospital of Pittsburgh, Exercise, Child, Patient, Pulmonary valve, Fluoroscopy, Hospital, Interventional cardiology, Dentistry, Medical device, Nursing, Tampa Bay

TAMPA, Fla., Oct. 3, 2023 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone recently, implanting its 250th congenital transcatheter heart valve.

Key Points: 
  • TAMPA, Fla., Oct. 3, 2023 /PRNewswire/ -- The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone recently, implanting its 250th congenital transcatheter heart valve.
  • "Most importantly, this means that we allowed 250 patients in need of pulmonary or tricuspid valve replacement to avoid open-heart surgery."
  • He was born with pulmonary stenosis, a heart defect in which the pulmonary valve is narrowed and opens poorly.
  • Pino underwent open-heart surgery when he was 9 years old to open up the narrowed valve, trading blockage for leakage.

Cardiost, Inc. Strengthens Scientific Advisory Board with Renowned Cardiovascular Experts, Advances Prototype Development with OEDIT Grant Support

Retrieved on: 
Friday, September 29, 2023
Medical device, University, Heart failure, Interventional cardiology, Lung transplantation, HF, Johnson & Johnson, Clinical trial, Coronavirus Scientific Advisory Board, Research, The Journal of Heart and Lung Transplantation, Biomedical engineering, Universidad, PCI, Harvard Medical School, IMACS, University of Los Andes (Colombia), CO, Journal, Wallace H. Coulter Department of Biomedical Engineering, User experience, Mount Sinai Medical Center, Publication, Biomedicine, MD, Montefiore Medical Center, Cardiology, Universidad de los Andes, Internal medicine, Fort Collins, Colorado, Journal of Cardiac Surgery, LVAD, Ventricular assist device, Hospital, MCS, Massachusetts General Hospital, CFD, Pharmaceutical industry, Heart, Patient

Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.

Key Points: 
  • Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.
  • The LAUD is a durable mechanical circulatory support (MCS) device to treat late-stage patients suffering from heart failure (HF).
  • Cardiost is focused on developing cardiovascular devices medical devices in the cardiovascular space.
  • “We are thrilled to add Dr. Goldstein and Dr. Moreno to our Scientific Advisory Board, both KOLs in their respective fields – MCS the former and PCI the latter.

Canon Medical introduces Alphenix Sky 12 HD interventional system with the new 12”×12” High-Definition (Hi-Def) Detector

Retrieved on: 
Tuesday, September 12, 2023
HD, HD-PLC, IO, Interventional cardiology, Canon Medical Systems Corporation, Interventional radiology, Neuroradiology, Patient, Patient safety, Interventional oncology, Cardiology, Blood vessel, SVP, Medical imaging

Tustin California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Tustin, CA, USA, 12th of September 2023 – Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD interventional system with our proprietary high-resolution HD 76 Hi-Def detector.

Key Points: 
  • Tustin California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Tustin, CA, USA, 12th of September 2023 – Continuing its focus on providing clinicians with clarity and precision during interventional procedures, Canon Medical Systems Corporation is introducing this technology for the Alphenix Sky 12 HD interventional system with our proprietary high-resolution HD 76 Hi-Def detector.
  • The new Alphenix Sky 12 HD with 12”×12” Hi-Def detector can help improve visualization during Interventional Cardiology (IC), Interventional Neurology (IN), Interventional Oncology (IO), and Interventional Radiology (IR), including pediatric procedures.
  • The Sky 12HD expands the Alphenix family by adding 12”x12” Hi-Def detector to its existing 12”x16” Hi-Def detector.
  • These options now provide clinicians the ideal size for their unique procedural needs, complimenting to the existing lineup of Alphenix Sky+, Alphenix 4D CT, Alphenix Biplane, and Alphenix Core+ systems.

Cardio Diagnostics Holdings, Inc Partners with Ascension Borgess Hospital’s Heart Attack Prevention Clinic on Coronary Artery Disease Study

Retrieved on: 
Wednesday, September 6, 2023
Cardiology, Biotechnology, Technology, Health, Pharmaceutical, Research, Artificial Intelligence, Hospitals, Surgery, Science, Clinical Trials, Partnership, American Heart Association, Interventional cardiology, Cardiovascular disease, CAD, Splenic infarction, Doctor of Philosophy, Hospital, Molina Healthcare, Myocardial infarction, Patient, Internal medicine, Coronary artery disease, CHD, Medical device, Pharmaceutical industry, Medical imaging

Dr. Gupta’s study aims to determine which new technologies should be routinely used to optimize the detection of asymptomatic coronary artery disease.

Key Points: 
  • Dr. Gupta’s study aims to determine which new technologies should be routinely used to optimize the detection of asymptomatic coronary artery disease.
  • With this study, Dr. Gupta and his team aim to identify effective coronary artery disease detection technologies to implement as the standard of care for patients cared for at the Heart Attack Prevention Clinic.
  • Cardio Diagnostics' epigenetic and genetic heart disease tests will be incorporated into an ongoing multi-year study alongside other CAD detection methods.
  • “We are excited to support Dr. Gupta’s groundbreaking research into optimized coronary artery disease detection,” said Cardio Diagnostics CEO Meesha Dogan, PhD.

SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor

Retrieved on: 
Thursday, August 24, 2023
Intervention, American Heart Association, Interventional cardiology, Acquisition, MD, Cardiology, OTC, 38th AVN Awards, Night, Growth, Montreal Heart Institute, IBN, Medical device

Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor.

Key Points: 
  • Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor.
  • Baron Night, SOHM president and CEO, said Dr. Bhat has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology.
  • Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
  • Dr. Bhat is a renowned Clinical and Interventional Cardiologist who has authored over 16 medical scientific publications.

Magenta Medical Completes Enrollment to Early Feasibility Study for World's Smallest Heart Pump

Retrieved on: 
Tuesday, August 22, 2023
Heart, Abdominal aortic aneurysm, Cardiogenic shock, Interventional cardiology, Aneurysm, Cardiac catheterization, Northwell Health, Splenic infarction, Quality of life, Nasiriyah Heart Center, Magenta, Artery, Federal, IVUS, Atherosclerosis, Teaching hospital, PCI, North Shore University Hospital, LAD, Mount Sinai Hospital, Patient, Risk, Elevate, St. Francis Hospital, Hospital, Coronary artery disease, FDA, Mount Sinai Health System, Groin, Safety, Pharmaceutical industry, Medical device, Nursing, Cardiology

KADIMA, Israel, Aug. 22, 2023 /PRNewswire/ -- Magenta Medical, developer of the world's smallest heart pump, announced today the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication. All 15 study patients were enrolled and successfully treated at Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital. The Elevate™ Early Feasibility Study was approved by the FDA to evaluate the safety and feasibility of the Elevate™ System in providing temporary mechanical circulatory support during HR-PCI procedures, and constitutes the first step in a clinical program intended to secure approval for the device in the US for this indication.

Key Points: 
  • KADIMA, Israel, Aug. 22, 2023 /PRNewswire/ -- Magenta Medical , developer of the world's smallest heart pump, announced today the completion of enrollment to its FDA-approved Early Feasibility Study with the Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication.
  • All 15 study patients were enrolled and successfully treated at Mount Sinai Hospital, St. Francis Hospital and Heart Center, and North Shore University Hospital.
  • "Having now used the system in nine complex, high-risk PCI cases, I can truly appreciate its advantages," said Dr. Sharma.
  • The percutaneous Elevate™ heart pump is inserted over a guidewire through commercially available 10 Fr introducer sheaths that require a small puncture in the groin.